VF
CHRS icon

Virtu Financial’s Coherus Oncology CHRS Stock Holding History

Virtu Financial’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25,835
Closed -$44K – 1671
2026
Q1 		$44K Buy
+25,835
New +$45.9K ﹤0.01% 1306
2025
Q3 		– Sell
-24,865
Closed -$18K – 1533
2025
Q2 		$18K Buy
+24,865
New +$21.5K ﹤0.01% 1262
2024
Q2 		– Sell
-39,167
Closed -$94K – 1372
2024
Q1 		$94K Buy
+39,167
New +$96.4K 0.01% 929
2023
Q3 		– Sell
-39,021
Closed -$167K – 1374
2023
Q2 		$167K Buy
+39,021
New +$230K 0.01% 868
2018
Q3 		– Sell
-10,414
Closed -$146K – 1598
2018
Q2 		$146K Sell
10,414
-6,972
-40% -$99.8K 0.01% 1581
2018
Q1 		$192K Buy
+17,386
New +$190K 0.01% 1379

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Virtu Financial's CHRS Position: Q2 2026 in Review

Virtu Financial sold out of Coherus Oncology (CHRS) in Q2 2026, closing a stake of 25,835 shares — an estimated $44K sold.

Virtu Financial first reported a position in CHRS in Q1 2018 and held it in 6 quarters. The position peaked at $192K in Q1 2018. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Virtu Financial reported no remaining Coherus Oncology position as of Q2 2026 after selling out during the quarter.
  • Virtu Financial sold 25,835 Coherus Oncology shares in Q2 2026, an estimated $44K.
  • Virtu Financial first reported a position in Coherus Oncology in Q1 2018 and held it in 6 quarters.
  • Virtu Financial's Coherus Oncology position peaked at $192K in Q1 2018.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.